ASLAN Pharmaceuticals (ASLN)
(Delayed Data from NSDQ)
$0.44 USD
+0.01 (1.98%)
Updated May 17, 2024 04:00 PM ET
After-Market: $0.45 +0.01 (1.42%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Brokerage Reports
ASLAN Pharmaceuticals Ltd. [ASLN]
Reports for Purchase
Showing records 41 - 60 ( 100 total )
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Nervous Markets, But We See Outperforming Names: H.C. Wainwright''s 2022 Top Picks
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Phase 2b Atopic Dermatitis Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Strategic Collaboration Inked for Upcoming Clinical Studies; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
3Q21 Financial Results; Biomarker Collaboration Effected; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Positive Phase 1 Top-Line Data in Atopic Dermatitis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
ASLAN004 Data Imminent; 2Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Secured Loan Facility Established to Advance ASLAN003; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
2020 Financial Results Reported; ASLAN004 Clinical Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Positive ASLAN004 Dermatitis Data; Financing Complete; Raising PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
ASLAN003 Appears Least Hepatotoxic Among DHODH Inhibitors; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
ASLAN004 Atopic Dermatitis Trial Opens Expansion Cohort; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Atopic Dermatitis Data Readout Nears; 3Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Enrollment Starts for Third Cohort in Atopic Dermatitis Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Advancing ASLAN003 in Autoimmune Diseases; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Atopic Dermatitis Study Advancing; More Clinical Sites Added; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
2Q20 Financial Results; Patient Recruitment to Resume Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
ASLAN004 Recruitment Paused; Interruption Transient; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y